Metabolic effects of biosynthetic human proinsulin in type 2 diabetes mellitus

European Journal of Clinical Investigation
R KlauserG Schernthaner

Abstract

Due to a longer plasma half-life and half-time of action on glucose metabolism biosynthetic human proinsulin was thought to be an alternative to long-acting insulin preparations. To test this hypothesis we studied 23 type 2 diabetic patients who could no longer be treated sufficiently with oral hypoglycaemic agents. After an initial 1 week phase during which all patients received protamine bound insulin twice daily, the patients either continued on NPH insulin (Group A, n = 11) or were randomly switched to human proinsulin (Group B, n = 12). Glucose profiles and peripheral and hepatic insulin sensitivity (euglycaemic clamp: 120 mU m-2 min-1) were measured at the end of the initial period (Time 1) and 1 week later (Time 2). The insulin-mediated glucose disposal (RD) was not changed after either treatment (group A: 176 +/- 18 vs. 192 +/- 19 mg m-2 min-1; group B: 175 +/- 15 vs. 174 +/- 12 mg m-2 min-1 for times 1 and 2, respectively, NS). Suppression of hepatic glucose output (HGO) was complete in both groups at both times. Fasting blood glucose levels (FBG) and basal HGO were equally low at times 1 and 2 (group A: FBG 118 vs. 123 mg dl-1, BHGO 81 vs. 79 mg m-2 min-1; group B: FBG 118 vs. 106 mg dl-1, BHGO 87 vs. 84 mg m-2 min-1;...Continue Reading

References

Jul 1, 1978·The Medical Clinics of North America·J A Galloway, R Bressler
Jun 1, 1975·The Journal of Clinical Investigation·D L HorwitzA H Rubenstein
Mar 1, 1987·The Journal of Clinical Endocrinology and Metabolism·R M CohenA H Rubenstein
Feb 13, 1970·Science·S E Fineberg, T J Merimee
Feb 1, 1970·Diabetes·A A SteeleD B Stone
Mar 1, 1970·The Journal of Clinical Investigation·N R LazarusL Recant
Jun 1, 1984·The Journal of Clinical Endocrinology and Metabolism·R R ReversJ M Olefsky
Jun 1, 1984·The Journal of Clinical Endocrinology and Metabolism·R M BergenstalK Steiner
Oct 1, 1982·Diabetes·R N FrankM A Cronin
Oct 1, 1981·The Journal of Clinical Investigation·O G KoltermanJ M Olefsky
Sep 25, 1959·Annals of the New York Academy of Sciences·R STEELE
Feb 1, 1967·Proceedings of the National Academy of Sciences of the United States of America·D F Steiner, P E Oyer

❮ Previous
Next ❯

Citations

Apr 1, 1993·Journal of Diabetes and Its Complications·J S Yudkin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.